Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes. The same bnAbs also bind to recombinant, soluble trimeric immunogens based on the SOSIP design. While SOSIP trimers are close structural and antigenic mimics of virion Env, the extent to which their glycan structures resemble ones on infectious viruses is undefined. Here, we compare the overall glycosylation of gp120 and gp41 subunits from BG505 (clade A) virions produced in a lymphoid cell line with those from recombinant BG505 SOSIP trimers, including CHO-derived clinical grade material. We also performed detailed site-specific analyses of gp120. Glycans relevant to key bnAb epitopes are generally similar on the recombinant SOSIP and virion-derived Env proteins, although the latter do contain hotspots of elevated glycan processing. Knowledge of native versus recombinant Env glycosylation will guide vaccine design and manufacturing programs. Display omitted •HIV envelope glycans are central features of broadly neutralizing antibody epitopes•Recombinant mimetics of the HIV virus trimer are vaccine candidates•Glycosylation of a leading trimer immunogen is similar to that of infectious virus Struwe et al. present site-specific analyses of N-glycosylation sites on HIV-1 envelope glycoproteins from an infectious virus and a recombinant trimer mimic. The structural and antigenic details of the glycan shield will be valuable for designing next-generation immunogens and understanding virus neutralization by broadly active antibodies.